Navigation Links
Use of a fast-acting insulin analog to control diabetic ketoacidosis in Children

Diabetic ketoacidosis (DKA) is a life-threatening condition that frequently requires hospitalization in children with type 1 diabetes.// The critical factors in the treatment of DKA include careful and frequent monitoring of the patient, skillful fluid and electrolyte adjustment, and the initiation of insulin therapy after the initial restoration of fluid volume has been achieved. Continuous low-dosage intravenous infusion of soluble insulin has been the procedure of choice for this because it provides direct control and results in a predictable rate of fall in serum glucose levels. However, admission to an intensive care unit to receive intravenous insulin infusion increases health care costs.

A recent study proposes using a subcutaneous fast-acting analog of human insulin instead of intravenous continuous regular insulin to avoid the need for a second intravenous line, simplify treatment of DKA in children, and provide a more economical solution. The aim of the study was to compare the efficacy of a subcutaneous fast-acting analog (lispro) with continuous intravenous regular insulin (CIRI) in the treatment of pediatric DKA.

The fluid replacement protocol aimed at correcting intravascular volume up to the normalization of the peripheral perfusion. Once cardiovascular stability was achieved, the child was alert, and vomiting has stopped, oral rehydration was started. Cerebral edema, the most feared complication of DKA, did not develop in the patients during this study. Also, there were no deaths or "near death" episodes, and no patient had to be treated with mannitol.

The study, published in the August issue of Diabetes Care concludes that DKA treatment with a subcutaneous fast-acting insulin analog represents a cost-effective and technically simplified procedure that precludes intensive care unit admission.


'"/>




Page: 1

Related medicine news :

1. Animal insulin product to be discontinued by drug major Eli Lilly
2. Brain stem cells to help in producing insulin
3. Now insulin can be inhaled
4. Exubera could mean the end of an insulin injection era for diabetics
5. Islet cells producing insulin cultivated in the lab
6. Pfizer vouches safety of long-term inhaled insulin.
7. Uncontrolled blood pressure
8. FDAs control is inherently weak
9. Drugs control and industry departments to share a common e-platform
10. Self control makes stress response easy
11. Progression of Glaucoma could be controlled with early detection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and ... the ultimate weight loss and wellness program, at their world headquarters of Omni La ... immediate and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology: